

AstraZeneca Development Pipeline 26 July 2007

Line Extensions

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Cardiovascular					
<i>Atacand</i>	angiotensin II antagonist	diabetic retinopathy	III	2009	2009
<i>Atacand Plus</i>	angiotensin II antagonist /thiazide diuretic	32/12.5 mg, 32/25 mg for hypertension	III	2H 2008	
<i>Crestor</i>	statin	atherosclerosis	III	Approved	Filed
<i>Crestor</i>	statin	outcomes CHF	III	1H 2008	1H 2008
<i>Crestor</i>	statin	outcomes End Stage Renal Disease	III	2009	2009
Gastrointestinal					
<i>Nexium</i>	proton pump inhibitor	NSAID GI side effects – symptom resolution	III	Promotable *	Filed
<i>Nexium</i>	proton pump inhibitor	NSAID GI side effects – ulcer healing	III	Launched	Filed
<i>Nexium</i>	proton pump inhibitor	peptic ulcer bleeding	III	1H 2008	1H 2008
<i>Nexium Sachet formulation</i>	proton pump inhibitor	GERD	III	Filed	Launched
<i>Nexium</i>	proton pump inhibitor	extra-oesophageal reflux disease	II	>2009**	>2009**
<i>Nexium low dose aspirin combination</i>	proton pump inhibitor	low dose aspirin associated peptic ulcer	III		2009
Neuroscience					
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	schizophrenia	III	Filed	Approved
<i>Seroquel</i>	D ₂ /5HT ₂ antagonist	bipolar maintenance	III	Q4 2007	Filed
<i>Seroquel</i>	D ₂ /5HT ₂ antagonist	bipolar depression	III	Q4 2007	Approved
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	generalised anxiety disorder	III	2H 2008	1H 2008
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	major depressive disorder	III	2H 2008	1H 2008
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	bipolar mania	III	1H 2008	1H 2008
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	bipolar depression	III	1H 2008	Q4 2007
Oncology & Infection					
<i>Faslodex</i>	oestrogen receptor antagonist	1 st line advanced breast cancer	III	>2009	>2009
<i>Faslodex</i>	oestrogen receptor antagonist	adjuvant	III	>2009	>2009
<i>FluMist (MedImmune)</i>	live, attenuated, intranasal influenza virus vaccine	influenza	III	1H 2008	Filed

* Authorities stated these symptoms were already captured within the GERD label. Text stating "No clinical interaction with naproxen or rofecoxib" was approved.

**Project Extraesophageal reflux disease (reflux asthma) will be completed but will not result in a regulatory filing.

Line Extensions (continued)

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Respiratory & Inflammation					
<i>Symbicort Turbuhaler</i>	inhaled steroid/fast onset, long-acting β_2 agonist	Symbicort Maintenance and Reliever Therapy for asthma (SMART)	III	Launched	
<i>Symbicort</i> pMDI	inhaled steroid/fast onset, long-acting β_2 agonist	asthma	III	Filed*	Launched**
<i>Symbicort</i> pMDI	inhaled steroid/fast onset, long-acting β_2 agonist	COPD	III	Filed*	1H 2008

* To be supplemented in 2008 with data supporting two additional strengths

** US approval based on 12 years and above

NCE's

Phase III

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Cardiovascular					
AZD6140	ADP receptor antagonist	arterial thrombosis	III	>2009	>2009
Saxagliptin	dipeptidyl peptidase-4 (DPP-4) inhibitor	diabetes	III	2009	1H 2008
Dapagliflozin	sodium-glucose cotransporter-2 (SGLT2) inhibitor	diabetes	III	>2009	>2009
Oncology & Infection					
<i>Zactima</i>	VEGF/EGF TKI inhibitor with RET kinase activity	NSCLC	III	2H 2008	2H 2008
<i>Recentin</i>	VEGF signalling inhibitor (VEGFR-TKI)	NSCLC and CRC	II/III	>2009	>2009
<i>Recentin</i>	VEGF signalling inhibitor (VEGFR-TKI)	recurrent glioblastoma	III	>2009	>2009
ZD4054	endothelin A receptor antagonist	hormone resistant prostate cancer	III	>2009	>2009
Motavizumab (MedImmune)	humanized monoclonal antibody	RSV prevention	III	2009	4Q 2007

NCE's

Phases I and II

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Cardiovascular					
<i>Crestor/fibrate</i>	statin + fibrate fixed combination	dyslipidaemia	II		2009
AZD0837	thrombin inhibitor	thrombosis	II	>2009	>2009
AZD1175		diabetes/obesity	I	>2009	>2009
AZD2207		diabetes/obesity	I	>2009	>2009
AZD1305	antiarrhythmic	arrhythmias	I	>2009	>2009
AZD6370		diabetes	I	>2009	>2009
AZD4121	cholesterol absorption inhibitor	dyslipidaemia	I	>2009	>2009
Gastrointestinal					
AZD9056	ion channel blocker (P2X7)	inflammatory bowel disease	II	>2009	>2009
AZD3355	inhibitor of transient lower oesophageal sphincter relaxations (TLESR)	GERD	II	>2009	>2009
Neuroscience					
PN400	naproxen + esomeprazole	signs and symptoms of OA and RA	II	>2009	2009
AZD3480	neuronal nicotinic receptor agonist	cognitive disorders in schizophrenia	II	>2009	>2009
AZD3480	neuronal nicotinic receptor agonist	Alzheimers	II	>2009	>2009
AZD2327	enkephalinergic receptor modulator	anxiety & depression	I	>2009	>2009
AZD5904	enzyme inhibitor	multiple sclerosis	I	>2009	>2009
AZD1080		Alzheimers	I	>2009	>2009
AZD3783		anxiety and depression	I	>2009	>2009
AZD3241		Parkinson's disease	I	>2009	>2009
AZD6765		depression	I	>2009	>2009
AZD0328		Alzheimers	I	>2009	>2009
AZD1940		nociceptive and neuropathic pain	I	>2009	>2009

Phases I and II (continued)

Oncology & Infection					
Zactima	VEGF/EGF TKI inhibitor with RET kinase activity	medullary thyroid cancer	II	2009	2009
CytoFab	anti-TNF-alpha polyclonal antibody	severe sepsis	II	>2009	>2009
AZD6244 (ARRY-142886)	MEK inhibitor	solid tumours	II	>2009	>2009
CAT-3888	recombinant immunotoxin hairy cell	hairy cell leukemia	II	>2009	>2009
AZD2281	PARP inhibitor	breast cancer	II	>2009	>2009
EBV vaccine* (MedImmune)		PTLD	II		>2009
AZD0530	SRC kinase inhibitor	solid tumours and haematological malignancies	I	>2009	>2009
AZD1152	aurora kinase inhibitor	solid tumours and haematological malignancies	I	>2009	>2009
AZD4769		solid tumours	I	>2009	>2009
AZD4877		solid tumours	I	>2009	>2009
AZD8931		solid tumours	I	>2009	>2009
AZD7762		solid tumours	I	>2009	>2009
AZD8330 (ARRY-424704)	MEK inhibitor	solid tumours	I	>2009	>2009
CAT-8015	recombinant immunotoxin	haematological malignancies	I	>2009	>2009
AZD2836 (Arrow)		hepatitis C	I	>2009	>2009
MEDI-534 (MedImmune)	RSV/PIV-3 vaccine	intranasal immunisation	I		>2009
MEDI-560 (MedImmune)	PIV-3 vaccine	intranasal immunisation	I		>2009
H5N1 (MedImmune)		pandemic influenza vaccine	I	TBA	TBA
MEDI-524 (Motavizumab) (MedImmune)	MAb targets F-Protein	early & late treatment of disease in paed > 1 yr	I		>2009
MEDI-561 (MedImmune)	HSP 90 inhibitor	solid tumours	I		>2009
MEDI-538 (MedImmune)	CD19 B cells	leukemia/lymphoma	I		>2009
MEDI-564 (MedImmune)	F protein inhibitor	RSV treatment	I		>2009

* Partnered products

Phases I and II (continued)

Respiratory & Inflammation					
AZD9056	ion channel blocker (P2X7)	rheumatoid arthritis	II	>2009	>2009
AZD1981		asthma	II	>2009	>2009
AZD5672		rheumatoid arthritis	II	>2009	>2009
MEDI-528 (MedImmune)	anti-IL-9 antibody	asthma	II		>2009
AZD4818		COPD	I	>2009	>2009
CAT-354	anti-IL-13 antibody	asthma	I	>2009	>2009
AZD5904		COPD	I	>2009	>2009
AZD1744		COPD	I	>2009	>2009
AZD1236		COPD	I	>2009	>2009
AZD9668		COPD	I	>2009	>2009
MEDI-563 (MedImmune)	anti-IL-5R antibody	asthma	I		>2009
MEDI-545 (MedImmune)	humanised antibody	SLE, Myositis	I		>2009
Pneumococcal vaccine * (MedImmune)		streptococcus pneumoniae	I		>2009

* Partnered products

NCE's

Pre Clinical

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Cardiovascular					
AZD8593		haemostasis	PC	>2009	>2009
AZD1283		thrombosis	PC	>2009	>2009
AZD5861		dyslipidaemia	PC	>2009	>2009
AZD1656		diabetes/obesity	PC	>2009	>2009
AZD3988		diabetes/obesity	PC	>2009	>2009
AZD3118		arrhythmias	PC	>2009	>2009
Gastrointestinal					
AZD2066		GERD	PC	>2009	>2009
AZD5329		functional GI disease	PC	>2009	>2009
Neuroscience					
AZD3102		Alzheimers	PC	>2009	>2009
AZD8797		multiple sclerosis	PC	>2009	>2009
AZD2066		analgaesia	PC	>2009	>2009
AZD6280		anxiety	PC	>2009	>2009
AZD2624		schizophrenia	PC	>2009	>2009
AZD1386		analgaesia	PC	>2009	>2009
AZD3043	GABA-A receptor modulator	short acting anaesthetic	PC	>2009	>2009
AZD7903		analgaesia	PC	>2009	>2009
AZD1704		analgaesia	PC	>2009	>2009
AZD7325		anxiety	PC	>2009	>2009

Pre Clinical (continued)

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Oncology & Infection					
AZD9935	VEGF signalling inhibitor (VEGFR-TKI)	solid tumours	PC	>2009	>2009
AZD0424	SRC kinase inhibitor	solid tumours	PC	>2009	>2009
AZD5180	anti-angiogenic	solid tumours	PC	>2009	>2009
AZD1845		solid tumours	PC	>2009	>2009
AZD9468		solid tumours	PC	>2009	>2009
AZD2932		solid tumours	PC	>2009	>2009
CAT-5001	recombinant immunotoxin	solid tumours	PC	>2009	>2009
AZD6918		solid tumours	PC	>2009	>2009
AZD4992			PC	>2009	>2009
AZD5099		infection	PC	>2009	>2009
AZD1480		range of tumours	PC	>2009	>2009
AZD6302		MRSA	PC	>2009	>2009
AZD8055		range of tumours	PC	>2009	>2009
AZD7295 (Arrow)		hepatitis C	PC	>2009	>2009
AZD6495		range of tumours	PC	>2009	>2009
MEDI-557 (MedImmune)	YTE – extended half-life RSV MAb	RSV Prophylaxis	PC		>2009
Respiratory & Inflammation					
AZD6067	protease inhibitor	COPD	PC	>2009	>2009
AZD6357		osteoarthritis	PC	>2009	>2009
AZD3825		asthma	PC	>2009	>2009
AZD5069		COPD	PC	>2009	>2009
AZD8848		asthma	PC	>2009	>2009
AZD8075		asthma	PC	>2009	>2009
AZD6605		osteoarthritis	PC	>2009	>2009
CAM-3001		rheumatoid arthritis	PC	>2009	>2009
AZD3199		asthma/COPD	PC	>2009	>2009

MedImmune Pre Clinical

Compound	Mechanism	Area under investigation	Phase	Estimated Filing	
				MAA	NDA
Oncology & Infection					
MEDI-536	hMPV/PIV-3 vaccine	respiratory infection	PC		>2009
hMPV MAb	hMPV MAb	respiratory infection	PC		>2009
MEDI-552	anti-CD20	leukemia/lymphoma	PC		>2009
MEDI-548	anti-EphB4 MAb	solid tumours	PC		>2009
MEDI-549	anti-Ephrin B2 MAb	solid tumours	PC		>2009
MEDI-555	anti-cMet	solid tumours	PC		>2009
MEDI-544	anti-EphA2 BiTE	solid tumours	PC		>2009
MEDI-562	hedgehog inhibitor	solid tumours	PC		>2009
MEDI-551	anti-CD19 MAb	leukemia/lymphoma	PC		>2009
MEDI-547	anti-EphA2 conj	solid tumours	PC		>2009
anti CEA BiTE	anti-CEA BiTE	solid tumours	PC		>2009
PIV-1 vaccine	PIV-1 vaccine	respiratory infection	PC		>2009
PIV-2 vaccine	PIV-2 vaccine	respiratory infection	PC		>2009
anti staph HP MAb	anti-staph HP MAb	infectious disease	PC		>2009
hMPV vaccine	hMPV vaccine	infectious disease	PC		>2009
anti Candida HP MAb	anti-Candida HP MAb	infectious disease	PC		>2009
Respiratory & Inflammation					
MEDI-546	anti-IFNaR MAb	inflammation	PC		>2009
MEDI-541	anti-HMGB-1 MAb	inflammation	PC		>2009
MEDI-551	anti-CD19 MAb	inflammation	PC		>2009
MEDI-552	anti-CD20 MAb	inflammation	PC		>2009
MEDI-553	anti-CD22 MAb	inflammation	PC		>2009
anti IL6 MAb	anti-IL6 MAb	inflammation	PC		>2009
anti RAGE MAb	anti-RAGE MAb	inflammation	PC		>2009
anti ICOS MAb	anti-ICOS MAb	inflammation	PC		>2009
anti YKL40 MAb	anti-YKL40 MAb	asthma/COPD	PC		>2009
anti Chitinase MAb	anti-Chitinase MAb	asthma/COPD	PC		>2009
anti C5a MAb	anti-C5a MAb	inflammation	PC		>2009

**AstraZeneca Development Pipeline
Discontinued Projects vs 1 February 2007 FY**

Cardiovascular & Gastrointestinal

NCE/Line Extension	Compound	Area under investigation
NCE	AZD2479	dyslipidaemia
NCE	AZD9684	thrombosis
NCE	AGI-1067	atherosclerosis
LE	<i>Seloken/Toprol-XL</i>	HCTZ combination
NCE	AZD6610	dyslipidaemia

Neuroscience

NCE/Line Extension	Compound	Area under investigation
NCE	AZD9272	neuropathic pain
NCE	AZD6538	neuropathic pain

Oncology & Infection

NCE/Line Extension	Compound	Area under investigation
NCE	AZD5896	solid tumours
NCE	AZD3646	solid tumours & haematological malignancies
LE	<i>Iressa BC</i>	breast cancer
NCE	AZD1689	solid tumours
NCE (MedImmune)	MEDI-507 (siplizumab) *	PTCL/CTCL
NCE (MedImmune)	MEDI-553 (anti CD22) *	leukemia/lymphoma
NCE (MedImmune)	MEDI-542*	solid tumours
NCE (MedImmune)	MEDI-556*	solid tumours
LE (MedImmune)	Synagis **	RSV

Respiratory & Inflammation

NCE/Line Extension	Compound	Area under investigation
NCE	AZD7928	COPD
NCE	AZD6703	rheumatoid arthritis
NCE	AZD1678	asthma
NCE	AZD2392	asthma
NCE	AZD9215	asthma

* Compound entered the pipeline in April 07, but has since been discontinued

** Minor activity ongoing, but will not lead to new indication/formulation

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

Abbreviations:

PC – Pre-clinical: Candidate Drug accepted for development but not yet administered to man.

MAA – Marketing Authorisation Application (Europe).

NDA – New Drug Application/Biologics Licensing Application (USA).